- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/535 - Granulocyte CSFGranulocyte-macrophage CSF
Patent holdings for IPC class C07K 14/535
Total number of patents in this class: 675
10-year publication summary
|
56
|
43
|
57
|
47
|
51
|
51
|
38
|
64
|
38
|
32
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Modernatx, Inc. | 1296 |
60 |
| Regeneron Pharmaceuticals, Inc. | 4362 |
16 |
| Institute for Research in Biomedicine (IRB) | 39 |
15 |
| Yale University | 2422 |
15 |
| Amgen Inc. | 4118 |
14 |
| Lipoxen Technologies Limited | 43 |
13 |
| Partner Therapeutics, Inc. | 27 |
13 |
| Emory University | 1641 |
12 |
| Replimune Limited | 41 |
12 |
| Children's Healthcare of Atlanta, Inc. | 247 |
11 |
| Elanco US Inc. | 733 |
11 |
| Ubiprotein, Corp. | 12 |
8 |
| IBC Pharmaceuticals, Inc. | 92 |
7 |
| Spectrum Pharmaceuticals, Inc. | 78 |
7 |
| Ambrx, Inc. | 182 |
6 |
| Gradalis, Inc. | 51 |
6 |
| Ningbo Innovative Mechanism Bioscience LLC | 7 |
6 |
| Hanmi Pharm. Co., Ltd. | 574 |
5 |
| The Jackson Laboratory | 348 |
5 |
| Octapharma AG | 203 |
5 |
| Other owners | 428 |